Erratum: Epicutaneous tolerance induction to a bystander antigen abrogates colitis and ileitis in mice (Inflammatory Bowel Diseases (2017) 23:11 (1972-1982) DOI: 10.1097/MIB.0000000000001273);Epicutaneous Tolerance Induction to a Bystander Antigen Abrogates Colitis and Ileitis in Mice

Inflammatory Bowel Diseases

Volumn 23, Issue 11, 2017, Pages 1972-1982

  Dunkin, David ^a   Berin, M Cecilia ^a   Mondoulet, Lucie ^b   Tobar, Steven ^a   Yeretssian, Garabet ^a   Tordesillas, Leticia ^a   Iuga, Alina ^c   Larcher, Thibaut ^d   Guillespie, Virginia ^a   Benhamou, Pierre Henri ^b   Colombel, Jean Frederic ^a   Sampson, Hugh A ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b DBV TECHNOLOGIES   (France)

^c New York Presbyterian Columbia University Medical Center   (United States)

^d LUNAM UNIVERSITÉ   (France)

Author keywords

bystander suppression; epicutaneous tolerance; inflammatory bowel disease; regulatory T cells

Indexed keywords

DEXTRAN SULFATE; INTERLEUKIN 10; OVALBUMIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; FORKHEAD TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT LOSS; COLITIS; CONTROLLED STUDY; EPICUTANEOUS TOLERANCE; HISTOPATHOLOGY; ILEITIS; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTE TRANSFER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; GENETICS; IMMUNOLOGY; INFLAMMATION; INTESTINE MUCOSA; METABOLISM; PATHOLOGY;

ANIMALS; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; ILEITIS; IMMUNE TOLERANCE; INFLAMMATION; INTERLEUKIN-10; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OVALBUMIN; T-LYMPHOCYTES, REGULATORY;

EID: 85040728706     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1093/ibd/izy241     Document Type: Erratum

References (43)

1. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005;128:1868-1878.
2. Torres J, Mehandru S, Colombel JF, et al. Crohn's disease. Lancet. 2017; 389:1741-1755.
3. Mori K, Yamanishi H, Ikeda Y, et al. Oral administration of carbonic anhydrase I ameliorates murine experimental colitis induced by Foxp3-CD4+CD25-T cells. J Leukoc Biol. 2013;93:963-972.
4. Shan-Shan Z, Yu-Lan L. Therapeutic effects of mucosal tolerance on experimental colitis in rats. Eur J Gastroenterol Hepatol. 2009;21: 1145-1152.
5. Yue M, Shen Z, Yu CH, et al. The therapeutic role of oral tolerance in dextran sulfate sodium-induced colitis via Th1-Th2 balance and gammadelta T cells. J Dig Dis. 2013;14:543-551.
6. Zhou P, Borojevic R, Streutker C, et al. Expression of dual TCR on DO11.10 T cells allows for ovalbumin-induced oral tolerance to prevent T cell-mediated colitis directed against unrelated enteric bacterial antigens. J Immunol. 2004;172:1515-1523.
7. Ben Ya'acov A, Lichtenstein Y, Zolotarov L, et al. The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis. BMC Gastroenterol. 2015;15:154.
8. Kraus TA, Cheifetz A, Toy L, et al. Evidence for a genetic defect in oral tolerance induction in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:82-88; discussion 81.
9. Kraus TA, Toy L, Chan L, et al. Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. Gastroenterology. 2004;126:1771-1778.
10. Dunkin D, Berin MC, Mayer L. Allergic sensitization can be induced via multiple physiologic routes in an adjuvant-dependent manner. J Allergy Clin Immunol. 2011;128:1251-1258.e2.
11. Azukizawa H, Dohler A, Kanazawa N, et al. Steady state migratory RelB+ langerin+ dermal dendritic cells mediate peripheral induction of antigenspecific CD4+ CD25+ Foxp3+ regulatory T cells. Eur J Immunol. 2011; 41:1420-1434.
12. Majewska-Szczepanik M, Yamamoto N, Askenase PW, et al. Epicutaneous immunization with phosphorylcholine conjugated to bovine serum albumin (PC-BSA) and TLR9 ligand CpG alleviates pneumococcal pneumonia in mice. Pharmacol Rep. 2014;66:570-575.
13. Mondoulet L, Dioszeghy V, Ligouis M, et al. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy. 2010;40:659-667.
14. Mondoulet L, Dioszeghy V, Vanoirbeek JA, et al. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol. 2011;154:299-309.
15. Van Kampen KR, Shi Z, Gao P, et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine. 2005;23:1029-1036.
16. Dioszeghy V, Mondoulet L, Dhelft V, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol. 2011;186:5629-5637.
17. Mondoulet L, Dioszeghy V, Larcher T, et al. Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS One. 2012;7: e31967.
18. Schmidt T, Lorenz N, Raker V, et al. Epicutaneous and oral Low-Zone tolerance Protects from colitis in mice. J Invest Dermatol. 2016;136:1831-1839.
19. Majewska-Szczepanik M, Goralska M, Marcinska K, et al. Epicutaneous immunization with protein antigen TNP-Ig alleviates TNBS-induced colitis in mice. Pharmacol Rep. 2012;64:1497-1504.
20. Dupont C, Kalach N, Soulaines P, et al. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol. 2010;125: 1165-1167.
21. Mondoulet L, Dioszeghy V, Puteaux E, et al. Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice. Clin Transl Allergy. 2012;2:22.
22. Tordesillas L, Mondoulet L, Blazquez AB, et al. Epicutaneous immunotherapy induces gastrointestinal LAP+ regulatory T cells and prevents food-induced anaphylaxis. J Allergy Clin Immunol. 2017;139:189-201.
23. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol. 2007;8:191-197.
24. Hadis U, Wahl B, Schulz O, et al. Intestinal tolerance requires gut homing and Expansion of FoxP3(+) regulatory T cells in the lamina propria. Immunity. 2011;34:237-246.
25. Mondoulet L, Dioszeghy V, Puteaux E, et al. Specific epicutaneous immunotherapy prevents sensitization to new allergens in a murine model. J Allergy Clin Immunol. 2015;135:1546-1557.e4.
26. Moolenbeek C, Ruitenberg EJ. The "Swiss roll": a simple technique for histological studies of the rodent intestine. Lab Anim. 1981;15:57-59.
27. Castaneda FE, Walia B, Vijay-Kumar M, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology. 2005;129:1991-2008.
28. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4 +CD25+ regulatory T cells. J Immunol. 2003;170:3939-3943.
29. Buruiana FE, Sola I, Alonso-Coello P. Recombinant human interleukin 10 for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2010:CD005109. doi: 10.1002/14651858.CD005109.pub3.
30. Armuzzi A, Pugliese D, Danese S, et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis. 2013;19:1065-1072.
31. Boschetti G, Nancey S, Sardi F, et al. Therapy with anti-TNFalpha antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:160-170.
32. Di Sabatino A, Biancheri P, Piconese S, et al. Peripheral regulatory T cells and serum transforming growth factor-beta: relationship with clinical response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2010;16: 1891-1897.
33. Kato K, Fukunaga K, Kamikozuru K, et al. Infliximab therapy impacts the peripheral immune system of immunomodulator and corticosteroid naive patients with Crohn's disease. Gut Liver. 2011;5:37-45.
34. Desreumaux P, Foussat A, Allez M, et al. Safety and efficacy of antigenspecific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology. 2012;143:1207-1217. e1-e2.
35. Corridoni D, Kodani T, Rodriguez-Palacios A, et al. Dysregulated NOD2 predisposes SAMP1/YitFc mice to chronic intestinal inflammation. Proc Natl Acad Sci U S A. 2013;110:16999-17004.
36. Kosiewicz MM, Nast CC, Krishnan A, et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest. 2001;107:695-702.
37. Pizarro TT, Pastorelli L, Bamias G, et al. SAMP1/YitFc mouse strain: a spontaneous model of Crohn's disease-like ileitis. Inflamm Bowel Dis. 2011;17:2566-2584.
38. Oida T, Zhang X, Goto M, et al. CD4+CD25-T cells that express latencyassociated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J Immunol. 2003;170: 2516-2522.
39. Chen Y, Kuchroo VK, Inobe J, et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994;265:1237-1240.
40. Miller A, Lider O, Roberts AB, et al. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A. 1992; 89:421-425.
41. Faria AM, Weiner HL. Oral tolerance and TGF-beta-producing cells. Inflamm Allergy Drug Targets. 2006;5:179-190.
42. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232-1236.
43. Choung RS, Princen F, Stockfisch TP, et al. Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis. Aliment Pharmacol Ther. 2016;43: 1300-1310.